Abstract
BackgroundCOVID-19 is a multisystemic disorder that frequently causes acute kidney injury (AKI). However, the precise clinical and biochemical variables associated with AKI progression in patients with severe COVID-19 remain unclear.MethodsWe performed a retrospective study on 278 hospitalized patients who were admitted to the ward and intensive care unit (ICU) with COVID-19 between March 2020 and June 2020, at the University Hospital, São Paulo, Brazil. Patients aged ≥ 18 years with COVID-19 confirmed on RT-PCR were included. AKI was defined according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria. We evaluated the incidence of AKI, several clinical variables, medicines used, and outcomes in two sub-groups: COVID-19 patients with AKI (Cov-AKI), and COVID-19 patients without AKI (non-AKI). Univariate and multivariate analyses were performed.ResultsFirst, an elevated incidence of AKI (71.2%) was identified, distributed across different stages of the KDIGO criteria. We further observed higher levels of creatinine, C-reactive protein (CRP), leukocytes, neutrophils, monocytes, and neutrophil-to-lymphocyte ratio (NLR) in the Cov-AKI group than in the non-AKI group, at hospital admission. On univariate analysis, Cov-AKI was associated with older age (>62 years), hypertension, CRP, MCV, leucocytes, neutrophils, NLR, combined hydroxychloroquine and azithromycin treatment, use of mechanical ventilation, and vasoactive drugs. Multivariate analysis showed that hypertension and the use of vasoactive drugs were independently associated with a risk of higher AKI in COVID-19 patients. Finally, we preferentially found an altered erythrocyte and leukocyte cellular profile in the Cov-AKI group compared to the non-AKI group, at hospital discharge.ConclusionsIn our study, the development of AKI in patients with severe COVID-19 was related to inflammatory blood markers and therapy with hydroxychloroquine/azithromycin, with vasopressor requirement and hypertension considered potential risk factors. Thus, attention to the protocol, hypertension, and some blood markers may help assist doctors with decision-making for the management of COVID-19 patients with AKI.
Highlights
The novel coronavirus disease (COVID-19) caused by the highly transmissible SARS-CoV-2 virus has shown diverse clinical manifestations and severe complications and has impacted health systems worldwide [1]
Cov-acute kidney injury (AKI) was associated with older age (>62 years), hypertension, C-reactive protein (CRP), MCV, leucocytes, neutrophils, neutrophil-to-lymphocyte ratio (NLR), combined hydroxychloroquine and azithromycin treatment, use of mechanical ventilation, and vasoactive drugs
Multivariate analysis showed that hypertension and the use of vasoactive drugs were independently associated with a risk of higher AKI in COVID-19 patients
Summary
The novel coronavirus disease (COVID-19) caused by the highly transmissible SARS-CoV-2 virus has shown diverse clinical manifestations and severe complications and has impacted health systems worldwide [1]. Severe COVID-19 may represent a type of hyperimmune disorder and can frequently cause acute respiratory failure in critically ill patients [3]. This disease affects other organs, and there is growing evidence of kidney dysfunction in SARS-CoV-2-infected patients [4,5,6]. COVID-19 is a multisystemic disorder that frequently causes acute kidney injury (AKI). The precise clinical and biochemical variables associated with AKI progression in patients with severe COVID-19 remain unclear
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
